Vijay Swarup

Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF

Shunichi Doi, Sho Kazui, Naoyuki Akashi, Ravi B. Patel et autres

us, de, au, nl, hr, at (code pays fourni par la source)

26-A-15223-ACC GROUP 2 AND EXERCISE-ONLY PULMONARY HYPERTENSION IN EXERTIONAL DYSPNEA: FINDINGS FROM A LARGE OUTPATIENT ASC COHORT

Gali Gannett, Jasmine Kaur, Somya Swarup, Akshay Sachdeva et autres

us (code pays fourni par la source)

26-A-13246-ACC POST-LAAC DYSPNEA AND EXERCISE HEMODYNAMICS IN HFPEF: AN ASC-BASED INVASIVE COHORT

Somya Swarup, Akshay Sachdeva, Jasmine Kaur, Sina Nafisi et autres

us (code pays fourni par la source)

26-A-11639-ACC FEASIBILITY AND DIAGNOSTIC YIELD OF OUTPATIENT EXERCISE RIGHT HEART CATHETERIZATION FOR DIFFERENTIATING HFPEF FROM PULMONARY VASCULAR DISEASE

Jasmine Kaur, Sankalp Malhotra, Somya Swarup, Scott M. Lilly et autres

us (code pays fourni par la source)

26-A-11728-ACC DISCORDANCE BETWEEN NONINVASIVE MARKERS AND EXERCISE HEMODYNAMICS IN HFPEF

Sankalp Malhotra, Jasmine Kaur, Somya Swarup, Akshay Sachdeva et autres

us (code pays fourni par la source)

26-CCC-13319-ACC BIDIRECTIONAL FLOW ≠ CLOSURE: HEMODYNAMIC TESTING GUIDES INTERATRIAL SHUNT MANAGEMENT

Somya Swarup, Akshay Sachdeva, Ravi Ghanta, Sina Nafisi et autres

us (code pays fourni par la source)

Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation

William Whang, Devi Nair, Rahul Bhardwaj, Marc K. Lahiri et autres

us (code pays fourni par la source)

TCT-581 Renal Sympathetic Denervation as Adjunctive Upstream Therapy during Atrial Fibrillation Ablation: Pooled Analysis of the HFIB and Ultra-HFIB Studies

Vivek Reddy, William Whang, Devi Nair, Marc K. Lahiri et autres

us (code pays fourni par la source)

Prospective Randomized Trial of Rotor Ablation vs Conventional Ablation for Persistent Atrial Fibrillation: REAFFIRM Trial

Johannes Brachmann, T. Vogtmann, John D. Hummel, Vijay Swarup et autres

Background Pulmonary vein isolation (PVI) is the cornerstone therapy for symptomatic drug‐refractory atrial fibrillation yet is not curative in a large segment of patients. Focal and rotational drivers are proposed to be involved in atrial fibrillation mechanisms but their ablation has produced …

hr, us, ca, nl (code pays fourni par la source)

Safety and Efficacy of a Novel Sealant‐Based Vascular Closure Device Following Electrophysiology Procedures: ReliaSeal Trial

John Summers, Vijay Swarup, Ian Parker, Joseph M. Bumgarner et autres

BACKGROUND: While manual compression (MC) remains the standard of care to achieve hemostasis, a novel vascular closure device (VCD) was designed to achieve faster hemostasis without compromising safety. The objective of the ReliaSeal trial was to evaluate the safety and effectiveness of …

us (code pays fourni par la source)

TCT-999 ReliaSeal Trial: A Randomized Trial of Multiple Venous Access Closure With MYNX CONTROL™ VENOUS Vascular Closure Device and Manual Compression After Catheter-Based Ablation Procedures

John Summers, Vijay Swarup, Joseph M. Bumgarner, Andrew Brenyo et autres

us (code pays fourni par la source)

Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial

Gregg W. Stone, JoAnn Lindenfeld, Josep Rodés‐Cabau, Stefan D. Anker et autres

BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. METHODS: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus …

us, es, de, nl, be, il, gr (code pays fourni par la source)